Exploring anxiety and depression risk factors in herpes zoster neuralgia patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify risk factors for anxiety and depression in patients suffering from herpes zoster neuralgia. Participants will undergo evaluations using the Hospital Anxiety and Depression Scale (HADS) to categorize them into groups based on their anxiety and depression levels. The study will collect and analyze clinical data, serum biomarkers, and functional brain MRI results to understand the relationship between these factors and the psychological conditions in affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age more than 18 years old
2. Diagnosed as herpes zoster neuralgia
3. Signing informed consent

Exclusion Criteria:

1. Unable to complete the scale assessment
2. History of mental illness

Where it's running

• Tongji hospital
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Yang Shuguang, M.D — Tongji medical college of Huazhong University of Science and technology
• Study coordinator: Yang Shuguang, M.D
• Email: yangsuperpro@163.com
• Phone: （+86）15071078161

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Recombinant Zoster Vaccine with ZFA01 Adjuvant in Adults 40+

  A two-part study tests a recombinant herpes zoster vaccine in healthy adults aged 40 and older to see if it boosts immune responses and is safe.

  Recruiting at 2 sites Phase 1/2 Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Guangxi, Nanning and 1 other locations · NCT07920172

• How long the live shingles vaccine protects you

  This will see if the live attenuated shingles vaccine keeps adults from the original Phase III trial protected against herpes zoster for up to six years after vaccination.

  Recruiting Jiangsu Province Centers for Disease Control and Prevention · Nanjing, Jiangsu · NCT07585370

• Recombinant zoster (Shingrix) to see if it lowers new dementia diagnoses in people 76 and older in Finland.

  This trial will test whether the Shingrix shingles vaccine lowers the chance of a new dementia diagnosis in people aged 76 or older who live in Finland.

  Recruiting at 8 sites Phase 4 GlaxoSmithKline · Espoo and 7 other locations · NCT07502560

• Erector spinae plane block versus transcutaneous radiofrequency for postherpetic neuralgia

  This project will see if erector spinae plane block or transcutaneous radiofrequency works better to reduce pain in adults with postherpetic neuralgia.

  Recruiting Diskapi Teaching and Research Hospital · Ankara · NCT07400640

• Lyophilized shingles mRNA vaccine safety and immune response

  This trial will test a lyophilized mRNA vaccine to see if it is safe and produces immune responses in adults aged 40 years and older.

  Recruiting Phase 1/2 Sinovac Biotech Co., Ltd · Xinjiang · NCT07400003

• Loxoprofen patch for relieving shingles pain

  This will test if adding a loxoprofen sodium patch to standard care reduces pain in adults with shingles.

  Recruiting Beijing Tiantan Hospital · Beijing · NCT07378059

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.